Photo Credit: peterschreiber.media
The following is a summary of “Leukocyte telomere length decreased the risk of mortality in patients with alcohol-associated liver disease,” published in the December 2024 issue of Endocrinology by Yi et al.
Leukocyte telomere length (LTL) has been studied as a potential indicator of prognosis in various diseases. However, the relationship between survival and cause-specific mortality in people with alcohol-associated liver disease (ALD) remains unclear.
Researchers conducted a retrospective study exploring the association between LTL and mortality risk in people with ALD.
They obtained LTL and survival data from the National Health and Nutrition Examination Survey (NHANES) 1999–2002. The connection between LTL and mortality was assessed using Cox regression models and stratified analyses. Restricted cubic spline (RCS) analysis was used to explore non-linear relationships. Sensitivity analyses evaluated the robustness of the findings.
The results showed that LTL was associated with reduced all-cause mortality (all P value< 0.05). The risk of cardiovascular disease (CVD)-related death was lower in the Q3 (P<0.001) and Q4 (P<0.001) groups compared to the Q1 group. Shorter LTL was linked to higher cancer-related mortality in the Q2 group (P=0.03). Longer LTL was associated with improved survival, particularly in people older than 65 years (P for trend <0.001) or men (P for trend = 0.001). The LTL, all-cause mortality, and cancer-related mortality showed an L-shaped correlation (P for non-linearity = 0.02 and P for non-linearity < 0.001, respectively), and 4 sensitivity analyses confirmed the robustness of these findings.
They concluded that longer LTL was linked to improved survival in people with ALD, reducing mortality related to CVD and cancer.
Source: frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1462591/full
